CVS · Earnings call · 2026Q2T · Full report
340B Program Uncertainty
CVS HEALTH Corp · 2026-08-05 · Importance 37 · Surprise 42 · In source text
Health Services experienced pressure in its 340B business during the second quarter of 2026, although broader Caremark outperformance fully offset the impact for the quarter. Management attributed the pressure partly to pharmaceutical manufacturers imposing restrictions on covered entities. The transition of large specialty drugs to generic status is creating additional pressure within the program. CVS remains confident in its 2026 Health Services outlook but expects 340B to be a headwind in 2027 without providing a specific dollar estimate.
Key facts
- Expect 2027 to include a 340B headwind and membership declines in Caremark, partially offset by specialty pharmacy strength and a robust generic portfolio in 2027.
- Caremark experienced pressure in its 340B business in the quarter and expects 340B to be a headwind in 2027.
- CVS does not publicly split out the various value pools in Caremark and did not provide specific sizing for 340B.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | mixed | probable | — | Expect 2027 to include a 340B headwind and membership declines in Caremark, partially offset by specialty pharmacy strength and a robust… |
| revenue | negative | probable | — | Caremark experienced pressure in its 340B business in the quarter and expects 340B to be a headwind in 2027. |